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On the basis of serologically defined cell-surface antigens, virally associated murine 
leukemias  have been classified  into two groups:  (a)  leukemias  induced by Friend, 
Moloney, and Rauscher (FMR+)  murine leukemia viruses (MuLV) 1 that display a 
common FMR  antigen  complex, and  (b)  leukemias that  display Gross cell-surface 
antigen (GCSA+). The latter include those induced by AKR/Gross MuLV and those 
occurring spontaneously in high leukemic strains such as AKR (1-5). 
Recently, it has been observed that  mice can  generate a  cell-mediated cytotoxic 
response to syngeneic MuLV-induced  tumor cells  (6-11).  The responses to tumors 
induced by the Moloney leukemia/sarcoma virus complex have been particularly well 
studied (reviewed in reference 6). Cytotoxic T cells have been raised that lyse a variety 
of syngeneic tumor cells bearing FMR antigens (7, 8). As cytotoxic T  cells stimulated 
by infection of mice with Friend, Moloney, or Rauscher MuLV reciprocally lysed a 
variety ofsyngeneic FMR+  GCSA-, but not syngeneic FMR-  GCSA+ or allogeneic 
FMR+  target  cells,  it  appeared  that  these  effector cells  were  H-2  restricted  and 
possibly directed against  common FMR  antigens  (7,  8).  The cytotoxic response to 
FMR+  tumors  may  not  invariably  be  H-2  restricted  (9,  10),  however,  and  can 
apparently be specifically directed against  Moloney, but  not  Rauscher  or Friend, 
virion antigens (11). 
In contrast  to the well-documented descriptions of effector cells directed against 
FMR  tumors, evidence suggesting  that  murine cytotoxic cells can be generated to 
syngeneic tumors bearing GCSA is rather limited. The latter are associated primarily 
with spontaneous leukemias, and, in general, these are less antigenic to the host than 
are leukemias induced by the exogenous FMR viruses (2,  12). However, an immune 
response  to  such  tumors  might  be  anticipated  because  resistance  to  Gross  virus- 
induced leukemia is governed in part by a locus (Rgv-1) that maps in the same region 
(K-I of H-2) as that which controls immune responsiveness (13-16). In further support 
of this  hypothesis,  studies  of humoral  immunity  in  mice  indicate  that  immune 
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responsiveness to the viral envelope proteins gp70 and p l5(E) of endogenous MuLV 
is coded in the H-2 region (17-18). 2 
Cytotoxic T  cells have  been  raised by repetitive in  vitro stimulation with  AKR 
MuLV  gp71 and were found to preferentially lyse a  virus-producing AKR tumor line 
when compared with an AKR embryo fibroblast line (19). In another study, relatively 
weak cytotoxic activity to an AKR  tumor line developed in several semisyngeneic Fz 
mice after immunization with this tumor (20). 
In the present study, we describe initial experiments aimed at determining whether 
the ability to generate cytotoxic activity against syngeneic GCSA +  tumors correlates 
with Rgv-directed resistance to leukemogenesis. As a first approach, we have examined 
the  ability of C57BL/6  mice  of resistant  Rgv  genotype  to  generate  cytolytic cells 
specific for the syngeneic tumor EdG2, which was originally induced by Gross virus 
and  is  the  prototype  cell  for  the  definition  of GCSA  antigen  (3,  4).  A  scheme  is 
described whereby such  cells were produced by allogeneic in vivo priming followed 
by secondary in vitro challenge with viral antigen-positive tumors of H-2 b histocom- 
patibility type. 
Materials  and  Methods 
Mice.  6- to 8-wk-old male C57BL/6, CBA, and AKR mice were obtained from The Jackson 
Laboratory  (Bar  Harbor,  Maine).  DBA/2  mice were  obtained  from  the  Fred  Hutchinson 
Cancer Research Center central animal facilities. Breeding pairs for the AKR. H-2  b congenic 
line were kindly provided by Dr. E. Boyse (Sloan-Kettering Institute, New York). 
Tumor  Cells.  A  spontaneous leukemia cell line derived from an AKR mouse  (AKR SL3) 
was maintained by weekly passage of leukemic spleen cells into AKR mice. These cells were 
used for in vivo immunization of C57BL/6 mice. In addition, a spontaneous leukemia which 
arose in  an AKR-H-2  b congenie mouse  (AKR.H-2  b SL1)  and  a  tumor of C57BL/6  origin 
(EdG2) originally derived by infection with Gross virus were similarly maintained in vivo by 
passage into C57BL/6 mice. These three tumor cell types were also passaged in vitro for use as 
target cells in SaCr-release assays or as stimulator cells. EL4  lymphoma  (H-2  b)  and  P815-Y 
mastocytoma (H-2  a) cells were maintained by serial passage of ascites fluid in syngeneic mice 
(C57BL/6 or DBA/2, respectively). 
The presence of the MuLV-encoded proteins gp70 and p30 on tumor cells was determined 
by complement-mediated lysis of 5~Cr-labeled target cells in microcytotoxicity assays. Target 
cells were incubated with various dilutions of goat anti-Rauscher gp70 serum, goat anti-AKR 
p30 serum,  or with a  rabbit antiserum raised against EL4 cells (21).  In general, these goat 
antisera directed against MuLV proteins identify primarily group-specific antigens. In all cases, 
exposure to antiserum was for 10 min at room temperature. Rabbit serum was then added at 
a  final concentration of 1:40,  and the mixtures further incubated for 50 rain at 37°C. At the 
end of this period, the cells were briefly centrifuged (300 g, 30 s), and a portion of the cell-free 
supernate assessed for its 51Cr content. Percent specific cytolysis was defined as 
x-y 
x  100; 
Z 
where x  =  51Cr released from target cells incubated with antibody and complement,y -- ~lCr 
released from target cells incubated with medium alone, and z  -- 5~Cr released from target cells 
after they have been frozen and thawed through three cycles (~ 80% of total). As stated in the 
legend to Table 1, the percent specific cytolysis observed when target cells were incubated with 
complement in the absence of added antibody was, with a single exception, ~  5%. 
Effector  Cells.  Cytotoxic cells were generated in  vivo by intraperitoneal immunization of 
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C57BL/6 mice with  l07 viable AKR SL3 cells. Peritoneal exudate cells (PEC), obtained 8 or 
more d  later, were collected by two washes of the peritoneal cavity with Hanks' balanced salt 
solution (HBSS, Grand Island Biological Co., Grand Island, N.Y.) containing 1 U/ml sodium 
heparin (A. H. Robins Co., Richmond, Va.). After three washes in HBSS, the number of viable 
cells was determined by erythrocin B dye exclusion, and the cells resuspended in RPMI-1640 
(Microbiological  Associates, Walkersville, Md.) containing 10% heat-inactivated (56°C, 30 min) 
fetal  calf serum  (FCS,  Grand  Island  Biological Co.),  100  U/ml  penicillin and  100  #g/ml 
streptomycin.  This  mixture  will subsequently  be  referred  to  as  assay  medium.  Single cell 
suspensions of spleens were made, and  contaminating erythrocytes lysed by treatment with 
0.83%  NH4CI. After removal of erythrocyte debris by brief centrifugation (300 g, 10 s), spleen 
cells were washed, counted, and suspended in assay medium. 
In vitro generated cytotoxic cells were obtained by culture of spleen cells from normal or in 
vivo primed C57BL/6 mice in assay medium further supplemented with 100 #g/ml gentamicin 
(Schering Corporation, Kenilworth, N.J.) and 2 mM L-glutamine (Grand Island Biological Co.) 
(supplemented medium). Spleen cells (107) were'cultured alone or together with l0  s, 2  ×  105, 
or 4  ×  104 irradiated (3,000 rad, 1arCs irradiator) or mitomycin C- (Sigma Chemical Co., St. 
Louis, Mo.) treated (100/~g/ml, 37°C, 45 rain) tumor cells in individual wells of Falcon 3008 
muhiwell  tissue culture plates (Falcon Labware, Div. of Becton, Dickinson & Co., Oxnard, 
Calif.) in a  total volume of 1.5 ml. After 5-7 d of culture (37°C, 95% air, 5% CO2), the cells 
were harvested, washed, counted, and suspended in assay medium for use in cytotoxicity assays. 
Cytotoxicity Assays.  Tumor cells or spleen cells previously cultured (3-4 d, 37°C, 95% air, 5% 
CO2)  in supplemented medium containing 10/Lg/ml Escherichia coli lipopolysaccharide (Difco 
Laboratories, Detroit, Mich.) were labeled with 5~Cr for use as target cells in microcytotoxicity 
assays as previously described (22).  Briefly, 104 51Cr-labeled target cells and varying numbers 
of effector cells were centrifuged together (300 g, 30 s) and then co-incubated in a total volume 
of 0.2  ml. After 4.5  h  at  37°C,  the cells were again centrifuged, and an  aliquot of cell-free 
supernate removed for assessment of its 5~Cr content. The percent specific lysis was defined as 
x-y 
X  100; 
z 
where x  --  51Cr released from  target cells incubated with effectors, y  =  51Cr released from 
target cells incubated with medium alone, and z  --  51Cr released from target cells after they 
have been frozen and thawed through three cycles (~ 80% of total). 
Spontaneous n]Cr release was that amount released when  target cells were incubated with 
medium alone, expressed as a percentage of the amount released by freeze-thawing. 
In "cold-target" competition assays, unlabeled target cells were also included in the reaction 
mixtures at ratios between  1  : 1 and 30:1  unlabeled to 5aCr-labeled target cells. 
Antisera Treatment of Effector Cells.  In some experiments, effector cells were preincubated, just 
before assessment of their cytotoxicity activity, with antisera (107 cells/ml, 25°C, 45 min). After 
centrifugation, treated cells (or untreated controls) were further incubated in a  1:20 dilution 
(in RPMI-1640) of rabbit serum as a complement source  (10  7 cells/ml, 37°C, 45 min). At the 
end of this period, the effector cells were washed three times, counted, and resuspended in assay 
medium at viable cell densities equivalent to those of untreated preparations. The AKR anti- 
Thy  1.2 serum used was a  gift of Dr. G. Klimpel, Fred Hutchinson Cancer Research Center 
(23).  Anti-Lyt 1.2 serum  ~vas a  gift of Drs. K-E. and I. Hellstrom, Fred Hutchinson  Cancer 
Research Center. The ~ ~ti-Lyt 2.2 serum was prepared by the method of Shiku et al. (24). The 
specificities of both anti-Lyt sera have previously been reported (25). 
Results 
Generation  of  Cytotoxic  Effector  Cells  against  a  Syngeneic  AKR/Gross  Virus-induced 
Tumor.  We  were  unable  to  induce  significant cytotoxic activity by  immunization 
with up to  108 irradiated F_~G2 cells, even when cells from such primed animals were 
subsequently restimulated with Et3G2 cells in vitro (data not shown). Consequently, 
C57BL/6  mice  were  immunized  with  107  cells of an  established  allogeneic  (H-2  k) 54  CYTOTOXIC T CELLS TO A SYNGENEIC MuLV+ TUMOR 
TAeLE  I 
Tumor Cells 
H-2 hap-  Tumor  Inducing agent  Mouse strain  lotype 
Virus-associated cell suro 
lace antigens* 
gp70  p30 
SL3  Spontaneous leukemia  AKR  k  + + +  + + 
Ec~G2  Gross virus  C57BL/6  b  + + +  + + + 
SL 1  Spontaneous leukemia  AKR. H-2  b  b  +  +  +  + 
EL4  Dimet hylbenzanthracene  C57BL/6  b  3=  - 
P815Y  Methylcholanthrene  DBA/2  d  -  - 
* The presence of the gp70 and p30 proteins of MLV on these tumor cells was determined by the ability 
of specific antisera and complement to lyse the cells (see Materials and Methods). A range of dilutions of 
each antiserum  was used; the values of positivity presented  are the values of percent  specific cytolysis 
obtained with 1:900 anti-gp70 and 1:300 anti-AKR p30 as follows: -, 0-10% lysis; =1=, 10-20%; +, 20- 
40%;  + +, 40-70%; and  + + +, 70-100%. These concentrations  of antisera were selected because they 
were the highest dilutions that caused the maximum amount of lysis of the positive cells. Greater than 50% 
lysis of all cell types tested  was observed when  a  1:900 dilution of a  rabbit anti-EL4 cell serum  and 
complement was used, indicating that all were susceptible to antibody and complement attack. The values 
for percent spontaneous release (cells incubated with medium alone) were all ~  10%. The values for percent 
specific lysis when target cells were incubated with complement but not antibody were ~  5% except for 
P815 cells which was ~  10%. 
leukemic line  (AKR SL3)  which  bears AKR/Gross  viral antigens  (Table I).  It was 
argued that a  response directed against virus-associated antigens common to both the 
allogeneic  (AKR  SL3)  and  syngeneic  (Ec3G2)  tumors  might  then  be  detected  by 
employing F~G2 as a  target cell. 
When  spleen or  PEC  were  harvested  10  d  after injection of AKR  SL3 cells and 
tested  in  short-term  51Cr-release assays, cytotoxic activity was observed against  the 
immunizing  allogeneic cell  but  not  against  E~G2  cells  (Table  II A).  In  a  typical 
experiment, PEC preparations contained much more activity against AKR  SL3 than 
did  spleen  cell  preparations  (Table  II  A).  Furthermore,  as  both  PEC  and  spleen 
effector cells lysed AKR  SL3 but not F_a3G2 (Table II A), EL4 (H-2b), or P815  (H-2  d) 
cells (data not shown), it seemed likely that only a eytotoxic response directed against 
alloantigens had been induced. 
In contrast, when spleen cells from the same primed mice (10 d  after 107 AKR SL3 
cells)  were  additionally  cultured  in  vitro  with  mitomycin  C-treated  Ec~G2  cells, 
substantial  lytic  activity  toward  ESG2  developed  (Table  IIB).  Strikingly,  such 
restimulation did not induce effector cells capable of lysing AKR SL3 cells. Unprimed 
spleen cells cultured with E~G2 cells never generated significant lytic activity (Table 
II B). On the other hand, restimulation in vitro of AKR SL3-primed spleen cells with 
the homologous tumor (AKR SL3) led to vigorous activity directed exclusively toward 
AKR  SL3 and thus presumably directed to alloantigen. Unprimed C57BL/6  spleen 
cells cultured with AKR  SL3 cells under the same conditions generated less activity 
toward AKR  SL3.  It thus appeared that  both  in vivo priming with allogeneic cells 
and in vitro restimulation with syngeneic cells were necessary to induce the develop- 
ment of lytic activity to the syngeneic tumor. 
The kinetics of in vivo priming with AKR  SL3 cells were studied by immunizing 
each of a  large group of C57BL/6 mice with  107 AKR SL3 cells. After 8-30 d, spleen 
cells were cultured alone or with AKR SL3 or Ec~G2 stimulator cells for an additional W. R. GREEN, R. C. NOWINSKI, AND C. S. HENNEY 
TABLE II 
Generation and Specificity of C57BL/6 Cytotoxic Effector Cells 
55 
Stimulation*  Effeetor cells  E/T ratio 
Percent specific lysis 
E4'G2(H-2  b)  SL3(H-2  k) 
A. 
B. 
1  ° in vivo 
None  Spleen cells  200:1  -0.8  -4.4 
PEC  50:1  -2.3  -2.8 
SL3  Spleen cells  200:1  1.2  13.0 
PEC  50:1  0  60.3 
1  °invivo  2  ° in vitro 
None  None  Spleen cells  100:1  6.7  10.0 
SL3  Spleen cells  100:1  5.9  38.9 
F~G2  Spleen cells  100:1  7.0  6.5 
SL3  None  Spleen cells  100:1  8.4  11.9 
SL3  Spleen cells  100:1  6.8  81.8 
EdG2  Spleen cells  100:1  65.4  6.4 
C57BL/6  mice were injected with 107 SL3 cells and killed 10 d later. The lytic activity of PEC and 
spleen cells was either measured  immediately  (part  A) or after 5 d of in vitro culture (part B). 
Although only one  E/T cell ratio is presented  for simplicity  in  part  B, two other ratios  were 
employed for each cell preparation. The average values for spontaneous release were 3.3 or 1.8%/h 
(SL3) and 2.8 or 3.7%/h (EdG2) for experiments A and B, respectively. 
5  d  before assessment of lytic activity. At some of the time-points, PEC  and spleen 
cells were assessed for activity without in vitro restimulation. 
Although  activity against  Ec~G2  cells was  never  observed  after  in  vivo  priming 
alone, spleen cells harvested 8-12 d after injection of AKR SL3 generated a subtantial 
amount  of activity toward EdG2 target cells when  restimulated with EdG2  (Fig.  1). 
Interestingly, spleen cells harvested  14-30 d  after priming with AKR  SL3 cells were 
consistently less responsive to  EdG2  stimulation  than  were  spleen cells taken  10  d 
after priming. In contrast, spleen cell populations harvested  14-30 d  after AKR  SL3 
priming still responded vigorously to challenge with AKR  SL3 cells in vitro (Fig.  1). 
Thus the ability to respond to allogeneic tumors appeared to persist longer than that 
to syngeneic cells (Fig.  1). 
Several  parameters  of  in  vitro  culture  were  examined  for  their  effect  on  the 
generation of activity toward F~G2, and the following observations were made (data 
not shown): 
(a)  The response of AKR  SL3-primed cells to  E(3G2  stimulation was  rarely seen 
after 3  d  of culture, peaked after 5  or 6  d, and remained undiminished through day 
7. 
(b)  Both  mitomycin  C-treated  and  irradiated  (3  ×  10 a rad)  EdG2  were  able to 
stimulate a  syngeneic cytotoxic response. 
(c) Both in vivo and in vitro passaged F_~G2 cells were suitable as stimulator cells. 
(d)  Several lots of FCS were  found  to  support  the development of lytic activity 
against E~G2, and the presence of 5  X  10  -5 M  2-mercaptoethanol did not augment 
such activity. 
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Fro.  1.  Development of the ability of SL3-primed spleen cells to generate cytotoxic cells after in 
vitro restimulation. 18 C57BL/6 mice were injected with 107 SL3 cells, and 3 mice were killed on 
each of the indicated days after immunization. Spleen cells were then cultured an additional 5 d in 
vitro by themselves or in the presence of mitomycin C-treated syngeneic EdG2 or allogeneic SL3 
cells at various responder to stimulator cell ratios (10:1, 50:1, or 250:1). Maximum activity against 
the homologous target at an effector to target (E/T)  ratio of 100:I for effector cells restimulated 
with EdG2 cells (O), and at an E/T ratio of 33:1 for effector cells restimulated with SL3 cells (C)), 
is plotted. Because the amount of allogeneic activity observed in parallel cultures of SL3-primed 
spleen cells incubated without restimulation was often considerable, this amount of activity has 
been subtracted from the indicated activities against SL3 cells. The error bars indicate the range of 
the actual duplicate determinations of percent specific lysis. 
against  AKR  SL3  or  E~G2  were  of thymic  origin, cells  of each  specificity were 
sequentially preincubated  with  various  dilutions  of  anti-Thy  1.2  antiserum  and 
complement just before assessment of lytic activity. As can be seen from the results of 
a  representative experiment (Fig. 2), cytotoxic cells directed against either Ec~G2 or 
AKR  SL3  were  essentially  identical  in  their  susceptibility to  anti-Thy  1.2  and 
complement. We thus consider that the effector cells directed against Ec~G2, like those 
against AKR SL3, are T  cells. 
It has been reported that C57BL/6 effector cells directed against syngeneic tumors 
are,  like their precursors, of the  Lyt  1 + 2 + 3 +  phenotype (26),  thus distinguishing 
them from C57BL/6 effector cells directed against H-2  d alloantigens which are Lyt 
2+3+  but  Lyt  1-  (29).  We  therefore  considered  it  of interest  to  determine  the 
display of Lyt antigens on the effector cells described in Table II. In the experiment 
shown  in Table III, the  cytotoxic activity of C57BL/6  effector cells raised against 
Ec~G2  tumor  cells  was  completely  abrogated  by  the  action  of  anti-Lyt  2.2  and 
complement, as was that of cytotoxic cells generated against allogeneic cells. Further- 
more,  and in keeping with  the report  of Shiku et  al.  (26),  the effector cell activity W. R. GREEN. R. C. NOWINSKI, AND C. S. HENNEY  57 
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FIO. 2.  Susceptibility to anti-Thy  1.2 serum and complement of 1257BL/6 effector cells raised 
against either syngeneie (Eo"G2) or allogeneic  (SL3) tumors. SL3-primed C57BL/6 spleen cells were 
restimulated with and tested against SL3 cells (O) or restimulated with and tested against EdG2 
cells (0). Untreated effector cells or effector cells preincubated with various dilutions of anti-Thy 
1.2 serum and/or complement (1:20 rabbit serum), were assayed at an effector to target cell ratio of 
100:1. The average percent spontaneous release was 2.4%/h for EdG2 and 4.8%/h for SL3 cells. The 
error bars indicate the range of the actual duplicate determinations of percent specific lysis. SL3- 
primed spleen cells cultured without restimulation caused 1.1 and 6.5% specific lysis of EdG2 and 
SL3 cells, respectively. 
TABLE III 
Lyt Phenotypes of C57BL/6 Cytotoxic T Cells 
Stimulation*  Percent specific lysis 
Treatment 
,1 ° in vivo  2°in vitro  SL3  EdG2 
SL3  SL3  None  58.9  ND:~ 
C only  54.1 
1:20 anti-Lyt 1.2  +  12  30.9 
1:20 anti-Lyt 2.2  +  C  7.5 
SL3  EdG2  None  ND  21.1 
C only  21.3 
1:20 anti-Lyt 1.2  +  C  2.0 
1:20 anti-Lyt 2.2  +  C  -1.3 
Spleen cells from C57BL/6 mice injected 11  d earlier with  l07 SL3 cells were cultured in 
vitro for 6 d with either irradiated SL3 or irradiated EdG2 cells. The data presented represent 
the amount of lytic activity observed when either untreated effector cells or those pretreated 
as indicated were assayed against the stimulating target cell at E/T ratios of 8:1  (anti-SL3 
effectors vs. SL3) or 75:1 (anti-EdG2 effectors vs. EdG2).  Additional E/T ratios were also 
tested. The average values for spontaneous release were 2.9%/h for EdG2 cells and 7.0%/h 
for SL3 ceils. The amount of anti-Lyt serum employed was empirically determined to be the 
highest dilution that would ablate either alloantigen-primed cytotoxic cells (anti-Lyt 2.2) or 
"helper" activity in antibody responses to sheep erythrocytes (anti-Lyt 1.2) (25). 
* Not determined. 
directed against syngeneic tumor, was ablated by the action of the anti-Lyt 1.2 serum. 
The  activity against  allogeneic target  cells was clearly less affected by  this reagent. 
Thus, the cytotoxic T  cells raised against EdG2 tumor cells appeared to bear both Lyt 
1.2 and Lyt 2.2 alloantigens. 
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TABLE IV 
Cytotoxic Specificity of Restimulated Spleen Cells  frorn SL3-Primed C57BL/6 Mice 
Stimulation*  Percent specific  lysis 
1  ° in vivo  2 ° in vitro 
E/T ratio 
H.2  k  H_2  b  H-2  d 
CBA 
SL3  EdG2  SLI  EL4  P815  blasts 
SL3  None 
SL3  SL3 
SL3  EdG2 
50:1  14.5  0.8  0.4  1.7  -2.3  -3.2 
17:1  5.4  -1.5  0.6  0.3  -2.4  -1.6 
6:1  1.6  -5.4  0.2  -0.5  -1.7  -1.1 
50:1  33.1  18.8  0.6  0.8  -1.4  0.2 
17:1  26.7  7.1  0  0.6  -1.7  -0.8 
6:1  11.9  3.1  0.7  -0.7  -1.4  -0.9 
50:1  17.2  2.9  35.3  32.5  -1.0  0 
17:1  6.5  --1.1  21.4  17.2  --1.7  --0.8 
6:1  2.5  --4.8  9.8  5.9  -- 1.2  --0.2 
Spleen cells from C57BL/6 mice injected  10 d earlier with 107 SL3 cells were removed and placed in tissue 
culture for 6 d  with or without additional  stimulation as shown before assessment of their lytic activity. 
The average values for spontaneous release were 3.7%/h  (SL3),  2.0%/h  (EdG2),  2.2%/h  (SL1),  2.4%/h 
(EL4),  10. l%/h (CBA blasts), and 2.5%/h (P815). 
specificity, effector cells generated against  EdG2 cells were assayed against  a  wide 
spectrum of target cells.  These included P815 mastocytoma cells of the unrelated H- 
2  d haplotype, normal CBA (H-2  k) spleen cells stimulated by lipopolysaccharide (CBA 
blasts), and two additional target cells of H-2  b haplotype: EL4 and AKR.H-2  b SL1, 
the  latter a  cell line derived from a  spontaneous  leukemia which  developed in  an 
AKR-H-2  b congenic mouse. As shown in Table I, EL4 and P815 cells were negative 
or weakly positive for display of gp70 and p30 viral antigens relative to the highly 
positive AKR SL3, Ec~G2, and AKR. H-2  b SL1 cells. 
In  a  representative  experiment  (Table  IV),  restimulation  of AKR  SL3-primed 
spleen cells with  Ec~G2 caused the development of lytic activity only to Ec~G2 and 
AKR.H-2  b SL1  target cells.  Interestingly, EL4 cells, though of H-2  b haplotype and 
weakly positive for gp70 display, were not lysed. Competition experiments were also 
carried out  with  these tumor cells.  In  these studies, effector cells induced by AKR 
SL3 priming followed by restimulation with EdG2 were tested against  SlCr-labeled 
Ec~G2 cells in  the presence of varying numbers of unlabeled target cells.  Although 
Ec~G2 and  AKR.H-2  b SL1  cells effectively inhibited  the lysis  of Ec~G2 cells, AKR 
SL3, P815, and EL4 cells and CBA blasts were not inhibitory (Fig. 3 b). 
There was some lytic activity against AKR SL3 in Ec~G2 restimulated cultures, but 
a comparable amount of activity was observed in cultures ofAKR SL3-primed spleen 
cells  incubated  without  further stimulation  (Table  IV).  This  activity presumably 
represented a  population of cytotoxic cells directed against  alloantigen because the 
activity was augmented by restimulation with AKR SL3 cells and was also directed 
against  CBA blasts  (Table IV), Because CBA blasts were lysed much less efficiently 
than AKR SL3 cells, competition experiments were performed to determine whether W. R. GREEN, R. C. NOWINSKI, AND C. S. HENNEY 
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FIG.  3.  Competitive inhibition ofC57BL/6 effector cells raised against SL3 or EgG2 cells. In Fig. 
3 a C57BL/6 effector cells raised by restimulation of SL3-primed spleen cells with SL3 were assayed 
against 5~Cr-labeled SL3 cells at an E/T ratio of 20:1  in the presence or absence of the indicated 
numbers of unlabeled  target  cells.  The  percent  specific  lysis of SL3  cells  by  primed  but  non- 
restlmulated spleen cells was  18.4%. The average percent spontaneous release was 6.5%/h.  In Fig. 
3 b C57BL/6 effector cells raised by restimulation of SL3-primed spleen cells with F~G2 cells were 
assayed against  BlCr-labeled  E6'G2  cells at  an  E/T  ratio of 50:1  in  the  presence or  absence of 
unlabeled cells. The percent specific lysis of E6'G2 cells by primed but non-restimulated spleen cells 
was 0.4%. The average percent spontaneous release was 2.0%/h. 
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effector cells raised by secondary stimulation with AKR SL3 cells were only directed 
against H-2  k alloantigens. When the lytic activity of AKR SL3-primed and restimu- 
lated  effector  cells  was  assessed  against  labeled  AKR  SL3  cells  in  the  presence  of 
varying  numbers  of  unlabeled  target  cells,  only  AKR  SL3  and  CBA  blasts  were 
effective competitive inhibitors of lysis (Fig. 3 a). In contrast to their ability to inhibit 
effector cells raised against the syngeneic tumor, EgG2 and AKR. H-2  b SL1 cells were 
not  inhibitory.  This  finding,  coupled  with  the  observation  that  CBA  blasts  were 
reproducibly more efficient competitor cells than were AKR SL3 cells, suggested that 
the predominant lytic activity raised against AKR SL3 cells was directed against H- 60  CYTOTOXIC T CELLS TO A SYNGENEIC MuLV+ TUMOR 
TABLE  V 
Ability of Tumor Cells to Stimulate the Generation of Cytotoxic T Cells  from SL3- 
Primed C57BL/6 Spleens 
Stimulation*  Percent specific lysis 
E/T ratio 
1  ° in vivo  2 ° in vitro  SL3  EdG2  SL1 
SL3  None 
SL3  SL3 
SL3  E~G2 
SL3  SLI 
SL3  EL4 
100:1  39.3  3.0  0.5 
33:1  20.9  0.1  0 
11:1  6.8  -0.3  -0.2 
100:1  67.8  2.8  0.4 
33:1  55.9  0.9  -1.0 
11:1  29.2  0.7  -0.9 
100:1  37.5  86.9  42.8 
33:1  22.1  71.5  31.4 
11:1  10.2  41.3  20.3 
100:1  39.4  82.1  42.7 
33:1  25.9  48.9  26.6 
11:1  10.0  20.3  10.8 
100:1  46.1  1.9  2.1 
33:1  29.2  1.1  -0.3 
11:l  12.0  0.1  0.4 
Spleen cells from C57BL/6 mice injected 9 d earlier with l0  7 SL3 cells were removed 
and placed in tissue culture for 6 d with or without additional stimulation as shown 
before assessment of their lytic activity. Three responder to stimulator cell ratios (10: 
1, 50:1, and 250:1) were employed  for each  type of 2 ° stimulation, and the data 
depicted for that giving the highest  amount of lysis (generally 50:1). The average 
values for spontaneous release were 4.9%/h (SL3), 2.8%/h (Et3G2), and 2.6%/h (SL1). 
2 k  alloantigens.  Thus,  in  this  immunization  regime  there  was  no  evidence  for  the 
presence of activity against viral or tumor-specific antigens. 
Specificity of Stimulator Cells  in  the  Generation of Lytic Activity  to Ec3G2 and AKR.H-2 b 
SL1  Targets.  To  determine  whether  the  susceptibility  of tumor  cells  to  attack  by 
effector  cells raised  against EdG2  correlated with  their ability to serve as stimulator 
cells in the generation of these cytotoxic T  cells, irradiated  AKR.H-2  b SL1  or EL4 
cells were co-cultured with AKR  SL3-primed spleen cells. Three responder to stimu- 
lator cell  ratios  were  used  (10:1,  50:1,  and  250:1).  Irradiated  EdG2  and  AKR  SL3 
cells  were  used  in  parallel  cultures.  In  a  typical  experiment,  lytic  activity  toward 
F~G2  and AKR-H-2 b SL1  cells developed only in cultures in which either of these 
two  cells  were  included  (Table V).  AKR. H-2  b  SLI  cells  appeared  to  be  nearly  as 
efficient  stimulator  cells  as  EdG2  cells,  although  they  were  usually  somewhat  less 
susceptible as target cells (Table V, Figs. 3 b  and 4). Consistent with their inability to 
serve  as  targets,  EL4  cells  were  also  ineffective  as  stimulator  cells.  As  previously 
observed (Tables II and IV), there was a comparable amount of activity to AKR  SL3 
in all cultures except those to which AKR  SL3 stimulator cells had been added. In an 
experiment not shown, P815 cells were unable to restimulate AKR  SL3-primed spleen 
cells to  develop  into effector  cells capable of lysing EdG2  cells although  significant W. R. GREEN, R. C. NOWINSKI, AND C. S. HENNEY  61 
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FIG.  4.  Competitive  inhibition  of C57BL/6  effector  cells  raised  against  SL1  cells.  Fig.  4  is  a 
composite of two separate experiments in which effector cells raised by restimulation of SL3-primed 
spleen cells with SLI  cells were assayed against ~lCr-labeled SL1 cells at an E/T ratio of 100:1  in 
the presence or absence of the indicated numbers of unlabeled target cells. The percent specific lysis 
of SL1  by these effector cells was  17.8 and 29.6% in two separate experiments. SL3-primed spleen 
cells cultured without  restimulation caused -0.7  or 3.4% specific lysis of SLI  cells. The average 
percent spontaneous release was 2.2%/h in one experiment and 3.7%/h in the other. 
lytic activity against P815 cells did develop. 
Specificity of Effector Cells Induced after Restimulation with AKR.H-2  b SL1.  The possi- 
bility that  the lyric activity generated by restimulation of AKR SL3-primed spleen 
cells with AKR. H-2  b SL1 cells might be entirely directed against specifieities shared 
by Ec~G2 and AKR.H-2  b SL1 cells was addressed (Table V). Inasmuch as the SL1 
line was  derived from an AKR. H-2  b congenic mouse, it seemed possible that  lytic 
activity might develop against  AKR alloantigens other than those encoded by H-2. 
However, restimulation of AKR SL3-primed spleen cells with AKR.H-2  b SL1 cells 
did  not  augment  the  lysis of AKR  SL3 cells,  which  should  be a  measure of such 
minor  alloantigen  activity  (Table V).  The  presence of significant  activity against 
AKR  SL3  in  all  cultures  of AKR  SL3-primed spleen  cells,  however,  might  have 
obscured the detection of such activity. To address this problem in a  more sensitive 
manner,  effector cells  obtained  by  restimulation  with  AKR.H-2  b  SL1  cells  were 
assayed  against  51Cr-labeled  AKR.H-2  b SL1  cells  in  the  presence of a  variety of 
unlabeled cells including AKR SL3. In a composite of two separate experiments (Fig. 
4), only slight inhibition by AKR SL3 cells was observed and then only at the highest 
cell number used. Furthermore, EdG2 cells were even more efficient than homologous 
AKR-H-2  b SL1 cells as unlabeled competitors. Taken together, these findings suggest 
that  the amount  of lytic activity that  develops against  "minor" AKR  alloantigens 
when AKR-H-2  b SL1 cells are used to restimulate AKR SL3-primed populations is 
small.  Other  target  cells  including  lipopolysaccharide-"blasts" of C57BL/6  spleen 
cells and EL4 cells were ineffective competitor cells, further indicating that the display 
of H-2  b alloantigens was not sufficient for recognition. 
Discussion 
In  the present  study we have described the production of C57BL/6 cytotoxic T 62  CYTOTOXIC T CELLS  TO A SYNGENEIC MuI.V + TUMOR 
cells against  tumor cell lines of homologous histocompatibility type which  display 
AKR/Gross viral antigens. The following findings seem pertinent in addressing the 
specifcity of these cytotoxic cells: 
(a) In vivo priming with allogeneic AKR/Gross viral antigen-positive cells (AKR 
SL3) was necessary for their generation (Table II). 
(b)  In vitro restimulation with cells of H-2  b haplotype strongly positive for viral 
antigens  (F~G2 or AKR.H-2  b SL1)  was also necessary for their generation;  AKR 
SL3 cells or weakly gp70-positive EL4 (H-2  b) cells were ineffective (Tables II, IV, and 
v). 
(c) The effector cells raised in this manner recognized only E~G2 and AKR. H-2  b 
SL1 cells as target cells, not AKR SL3, EL4, or P815 (H-2  d) cells, or CBA (H-2  k) or 
C57BL/6 (H-2  b) spleen cell blasts (Table IV, Figs. 3 and 4). 
Spleen cells were able to respond to Ec~G2 stimulation after priming with AKR 
SL3 cells, but not after priming with large numbers (up to 10  a) of AKR spleen cells, 
even though the latter lead to a  significant allogeneic cytotoxlc response (data not 
shown). These observations imply that AKR SL3, Ec~G2, and AKR.H-2  b SL1 cells 
may  share  common  antigenic  specificities  against  which  the  cytotoxic  cells  are 
directed. Serological studies (Table I) suggest that these specificities might be AKR/ 
Gross virus-encoded products, although "derepressed" or modified cellular-specified 
antigens could also be candidates. These considerations and the fact that the suscep- 
tible AKR.H-2  b SL1  cells, though of H-2  b haplotype, are of the same AKR back- 
ground  as  are  the  insusceptible  AKR  SL3  cells  argue  for the  possibility  that  the 
effector cells  are  H-2  restricted  and  directed  against  AKR/Gross  virus-associated 
antigens. 
There are, of course other possible explanations for the observed specificity. It is 
conceivable, for example, that the AKR SL3 cells do not bear the antigens which the 
effector cells recognize on E~G2 and AKR.H-2  b SL1  cells.  Thus, even though the 
allogeneic AKR  SL3  cells  were  able  to  "prime"  for responsiveness  to  subsequent 
F~G2 stimulation, while AKR spleen cells bearing the same alloantigens were not, 
priming may be a  result of a  unique ability to AKR SL3 cells to induce a  response 
that  dramatically amplifies the ability to respond to weakly immunogenic antigens 
common to Ec~G2 and  AKR.H-2  b SL1  cells.  These antigens  could be confined to 
E~G2 and AKR-H-2  b SL1  or, if the cytotoxic cells are  indeed restricted, be more 
ubiquitously distributed. 
Formal determination of whether the effector cells are H-2 restricted depends on 
the definition of the antigens recognized and their introduction into cells of a variety 
of H-2 haplotypes. As a  first approach to the issues of specificity and restriction, we 
are currently attempting to infect cells of H-2  b haplotype that are not susceptible to 
effector cells raised against F~G2 (such as EL4). If we are able to convert insusceptible 
target  cells  to susceptible ones by infection with  virus preparations  from E~G2 or 
AKR SL3, we will not only demonstrate that the antigen recognized is virus associated, 
but will also have a system to address the question of restriction. 
The possibility that  AKR  SL3 cells may release infectious virus in vivo must  be 
considered in light of the observations that priming can be accomplished by injection 
of AKR SL3 but not by AKR spleen cells or by irradiated Ec~G2 cells. Thus, priming 
may occur by the release of virions that  infect host cells and  induce the display of 
antigens  recognized on susceptible  target  cells.  Priming by an  infectious process is W. R. GREEN, R. C. NOWINSKI,  AND C. S. HENNEY  63 
appealing because in vitro cultured AKR SL3 cells do release infectious virus (28), 
and because such an infection of host cells is easily reconciled with the postulate H-2 
restricted nature of the cytotoxic T  cells. 
An alternative explanation for the observation that, of the cell types tested, only 
AKR SL3 has the ability to "prime," is the possibility that initial stimulation by both 
alloantigens and the target cell antigen is required. Although it is unclear whether 
dual presentation of target cell antigen and alloantigen is necessary in the present 
system, there is a  precedent for this kind of stimulatory requirement. Zarling et al. 
(29)  have observed that when lymphocytes from leukemic patients in remission are 
concurrently stimulated with  a  mixture of autologous  leukemic cells  and  normal 
allogeneic cells, cytotoxic cells directed against  the autologous leukemic cells were 
produced. The leukemic cells themselves failed to stimulate such activity. Arguing by 
analogy, one might predict that simultaneous immunization with the syngeneic Ec~G2 
tumor and allogeneic cells might also prime spleen cells to subsequently respond to 
F_,dG2 stimulation in vitro. These experiments are presently underway. If this proves 
to  be  the  case,  such  findings coupled  with  Zarling's observations  might  establish 
general guidelines for inducing cytotoxic responses to syngeneic tumors. 
Although the manner in which spleen cells are primed in vivo and the absolute 
specificity of the cytotoxic cells directed against Ec~G2 thus remain unresolved, the 
nature  of these  cytotoxic cells is  considerably better  defined.  Effector cells raised 
against the syngeneic tumor by priming with AKR SL3 and restimulation with EdG2 
cells were as susceptible to the action of anti-Thy 1.2 serum and complement as were 
effector cells of allogeneic specificity that were also raised by secondary stimulation 
(Fig.  2).  This observation argues that  the effector cell that  lyses EdG2  is a  T  cell 
rather than a natural killer (NK) cell. The latter, although they have been reported 
to  bear Thy  1 alloantigen, display significantly less of this  alloantigen than do T 
effector cells (30, 31). Additional evidence against the participation of an NK effector 
cell in the phenomenon reported  here includes the following: (a)  the effector cells 
described require prolonged in vitro culture for their induction (NK cells are generally 
considered to be labile under "standard" culture conditions; 31), and (b) the effector 
cells described showed marked target cell specificity (NK cells do not display such 
stringent preference with respect  to either H-2  or tumor cell type;  32).  Moreover, 
AKR SL3 cells, which were not  lysed or recognized  by the effector cells directed 
against E~G2 and AKR-H-2  b SL1  cells (Tables  IV and V,  Figs.  3 b  and 4), were 
found  to  be  equally or  more  susceptible  than  these  latter  tumors  to  NK cells of 
C57BL/6 origin (Green, W., and J. Durdik, unpublished observations). 
The lytic activity to syngeneic EdG2 cells was completely abolished by treatment 
with either anti-Lyt  1.2 or anti-Lyt 2.2  serum and complement  (Table III). These 
findings are thus compatible with earlier reports of Shiku et al.  (26) that C57BL/6 
cytotoxic ceils directed against syngeneic target cells are of the Lyt 1 + 2 +  phenotype. 
This conclusion is limited, however, by the observations that in syngeneic situations 
the  precursors  of cytotoxic cells may also  be  of Lyt  1 +2+  phenotype, and  these 
precursors may differentiate, during a long-term (24 h or more) lytic assay itself, into 
Lyt 1-2 +  effector cells (26, 33).  Even though the duration of cytotoxic assays in the 
present system was only 4.5 h, this possibility must be considered. 
The  activity of the  cytotoxic T  cells  raised  against  H-2  k alloantigens was  also 
completely ablated by treatment with anti-Lyt 2.2 serum and complement but only 64  CYTOTOXIC T CELLS TO A SYNGENEIC  MuLV + TUMOR 
partially reduced by anti-Lyt 1.2 serum and complement (Table III). This observation 
is  thus  generally  consistent  with  previous  findings  that  cytolytic  activity  toward 
alloantigens is much more susceptible to anti-Lyt 2.2 than to anti-Lyt 1.2 serum (27). 
Our finding that after appropriate stimulation, C57BL/6 mice have the ability to 
mount a substantial cytotoxic response against AKR/Gross viral antigen-positive cell 
lines  of H-2  b haplotype  may represent  an  in  vitro correlate of the  known  genetic 
resistance  of these  mice  to  Gross  virus-induced  leukemia.  Further  analysis  of the 
ability of other strains of mice will be required to determine whether such responsive- 
ness  does,  in  fact, correlate with  the  presence of genes at  the  Rgv-I or Rgv-2 loci 
which govern resistance to Gross virus. The possible association of responsiveness with 
the Rgv-1 locus will be especially interesting because the latter has been mapped in 
the K-I region of H-2  (13,  14)  where a  variety of genes governing immune respon- 
siveness have also been located  (15,  16).  Linkage of cytotoxic responsiveness against 
AKR/Gross virus-associated antigens to Rgv-l-determined resistance, if found, may 
thus be a contributing factor in the high incidence of spontaneous leukemia of certain 
strains of mice such as AKR. 
Summary 
Efforts  were  made  to  generate  C57BL/6  cytotoxic  effector cells  to  a  syngeneic 
leukemia  (EdG2)  bearing AKR/Gross virus antigens.  As we were unable to induce 
significant cytotoxic activity by immunization with up to  10  a irradiated  Ec~G2 cells, 
even when cells from such primed animals were subsequently restimulated with EdG2 
cells  in  vitro,  C57BL/6  mice were  immunized  with  an  aliogeneic,  virus-producing 
AKR leukemic cell line (AKR SL3). 
Peritoneal exudate cells and, to a lesser degree, spleen cells from these mice showed 
significant  lytic activity  toward  the  immunizing  allogeneic  tumor  but  not  toward 
EdG2. When spleen cells were harvested from animals ~  10 d after injection of AKR 
SL3 and rechallenged  in vitro with either EdG2 or AKR.H-2  b SL1, another tumor 
that  displays AKR/Gross virus antigens, then a  vigorous cytotoxic response against 
Ec~G2 and AKR. H-2  b SL1 was obtained. 
Effector cells generated by AKR SL3 priming followed by in vitro stimulation with 
EdG2  or  AKR.H-2  b SL1  lysed  only cells  of H-2  b haplotype which  were  strongly 
positive for the display of serologically detectable AKR/Gross virus antigens. Thus, 
AKR SL3 cells were not lysed nor were EL4 cells (H-2b; but only weakly positive for 
gp70).  Cells not  bearing the MuLV antigens  tested  for, such  as P815  mastocytoma 
cells  and  spleen  cell  "blasts"  from  C57BL/6  and  CBA  (H-2  k)  mice,  were  also 
insusceptible to attack. The cytotoxic effector cells induced bore Thy 1.2 alloantigen 
and were of the Lyt 1 -I- 2 +  phenotype. 
Collectively, these findings are consistent with the conclusion that the cytotoxic T 
cells raised against  EdG2  are directed  against AKR/Gross virus-associated antigens 
and are H-2 restricted. It will be of interest to determine the relevance of such effeetor 
cells  to  the  known  resistance of the C57BL/6  mouse  to AKR/Gross  virus-induced 
leukemia. 
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